Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells

This publication has 60 references indexed in Scilit:

• In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells
  European Journal of Immunology, 2002
• Biological and clinical developments in melanoma vaccines
  Expert Opinion on Biological Therapy, 2001
• Enrichment and detection of live antigen-specific CD4+ and CD8+ T cells based on cytokine secretion
  European Journal of Immunology, 1999
• A Phase I Trial of an HLA-A1 Restricted MAGE-3 Epitope Peptide with Incomplete Freundʼs Adjuvant in Patients with Resected High-Risk Melanoma
  Journal of Immunotherapy, 1999
• Modulation of Proteasomal Activity Required for the Generation of a Cytotoxic T Lymphocyte–defined Peptide Derived from the Tumor Antigen MAGE-3
  The Journal of Experimental Medicine, 1999
• Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
  Immunology Today, 1997
• Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor
  Immunity, 1997
• Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.
  The Journal of Experimental Medicine, 1996
• Antigen-selected T-cell receptor diversity and self-nonself homology
  Immunology Today, 1993
• A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.
  The Journal of Experimental Medicine, 1992